SWOG clinical trial number
SWOG-8609

VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
90%
Published
Abbreviated Title
VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer
Activated
09/15/1988
Closed
11/15/1990

Research committees

Lung Cancer

Publication Information Expand/Collapse

1997

Teniposide (VM-26) as a single drug treatment for patientss with extensive small cell lung carcinoma. A Phase II study of the Southwest Oncology Group.

PN Grozea;JJ Crowley;VA Canfield;L Kingsbury;SW Ross;GS Beltran;LR Laufman;GR Weiss;RB Livingston Cancer 80(6):1029-1033

1994

SWOG 8609 - a phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC)

V Canfield;P Grozea;J Crowley;R Livingston Lung Cancer 11(Suppl.1):102(#389)

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open